Report Detail
Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Insights, Forecast to 2025
- RnM3518078 |
- 12 June, 2019 |
- Global |
- 115 Pages |
- QYResearch |
- Pharma & Healthcare
Dipeptide Peptidase 4 (DPP-4) Inhibitors are a class of oral diabetes drugs that work by blocking the action of DPP-4, an enzyme which destroys a group of gastrointestinal hormones called incretins. Incretins help stimulate the production of insulin when it is needed (e.g. after eating) and reduce the production of glucagon by the liver when it is not needed (e.g. during digestion). They also slow down digestion and decrease appetite. So by protecting incretins from damage, DPP-4 inhibitors help regulate blood glucose levels.
Januvia (Sitagliptin), Galvus (Vildagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin) are the major DPP-4 drugs in the market.
The global Dipeptide Peptidase 4 (DPP-4) Inhibitors market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Dipeptide Peptidase 4 (DPP-4) Inhibitors market based on company, product type, end user and key regions.
This report studies the global market size of Dipeptide Peptidase 4 (DPP-4) Inhibitors in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Dipeptide Peptidase 4 (DPP-4) Inhibitors in these regions.
This research report categorizes the global Dipeptide Peptidase 4 (DPP-4) Inhibitors market by top players/brands, region, type and end user. This report also studies the global Dipeptide Peptidase 4 (DPP-4) Inhibitors market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Merck
Eli Lilly
AstraZenica
Boehringer Ingelheim
Takeda Pharmaceutical Company
BMS
Market size by Product
Sitagliptin
Saxagliptin
Linagliptin
Alogliptin
Vildagliptin
Market size by End User
Hospitals
Clinics
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Dipeptide Peptidase 4 (DPP-4) Inhibitors market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Dipeptide Peptidase 4 (DPP-4) Inhibitors market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Dipeptide Peptidase 4 (DPP-4) Inhibitors companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Dipeptide Peptidase 4 (DPP-4) Inhibitors submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Dipeptide Peptidase 4 (DPP-4) Inhibitors are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (g). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Dipeptide Peptidase 4 (DPP-4) Inhibitors market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size Growth Rate by Product
- 1.4.2 Sitagliptin
- 1.4.3 Saxagliptin
- 1.4.4 Linagliptin
- 1.4.5 Alogliptin
- 1.4.6 Vildagliptin
- 1.5 Market by End User
- 1.5.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size Growth Rate by End User
- 1.5.2 Hospitals
- 1.5.3 Clinics
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size
- 2.1.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue 2014-2025
- 2.1.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales 2014-2025
- 2.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Growth Rate by Regions
- 2.2.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Regions
- 2.2.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Manufacturers
- 3.1.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Manufacturers
- 3.1.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Manufacturers
- 3.1.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Concentration Ratio (CR5 and HHI)
- 3.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Manufacturers
- 3.2.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Manufacturers (2014-2019)
- 3.2.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Share by Manufacturers (2014-2019)
- 3.3 Dipeptide Peptidase 4 (DPP-4) Inhibitors Price by Manufacturers
- 3.4 Dipeptide Peptidase 4 (DPP-4) Inhibitors Manufacturing Base Distribution, Product Types
- 3.4.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Type
- 3.4.3 Date of International Manufacturers Enter into Dipeptide Peptidase 4 (DPP-4) Inhibitors Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Product
- 4.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Product
- 4.3 Dipeptide Peptidase 4 (DPP-4) Inhibitors Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Breakdown Data by End User
6 North America
- 6.1 North America Dipeptide Peptidase 4 (DPP-4) Inhibitors by Countries
- 6.1.1 North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Countries
- 6.1.2 North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Dipeptide Peptidase 4 (DPP-4) Inhibitors by Product
- 6.3 North America Dipeptide Peptidase 4 (DPP-4) Inhibitors by End User
7 Europe
- 7.1 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors by Countries
- 7.1.1 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Countries
- 7.1.2 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors by Product
- 7.3 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors by End User
8 Asia Pacific
- 8.1 Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors by Countries
- 8.1.1 Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Countries
- 8.1.2 Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors by Product
- 8.3 Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors by End User
9 Central & South America
- 9.1 Central & South America Dipeptide Peptidase 4 (DPP-4) Inhibitors by Countries
- 9.1.1 Central & South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Countries
- 9.1.2 Central & South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Dipeptide Peptidase 4 (DPP-4) Inhibitors by Product
- 9.3 Central & South America Dipeptide Peptidase 4 (DPP-4) Inhibitors by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors by Countries
- 10.1.1 Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Countries
- 10.1.2 Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors by Product
- 10.3 Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors by End User
11 Company Profiles
- 11.1 Merck
- 11.1.1 Merck Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Merck Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Merck Dipeptide Peptidase 4 (DPP-4) Inhibitors Products Offered
- 11.1.5 Merck Recent Development
- 11.2 Eli Lilly
- 11.2.1 Eli Lilly Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Eli Lilly Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Eli Lilly Dipeptide Peptidase 4 (DPP-4) Inhibitors Products Offered
- 11.2.5 Eli Lilly Recent Development
- 11.3 AstraZenica
- 11.3.1 AstraZenica Company Details
- 11.3.2 Company Business Overview
- 11.3.3 AstraZenica Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 AstraZenica Dipeptide Peptidase 4 (DPP-4) Inhibitors Products Offered
- 11.3.5 AstraZenica Recent Development
- 11.4 Boehringer Ingelheim
- 11.4.1 Boehringer Ingelheim Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Boehringer Ingelheim Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Boehringer Ingelheim Dipeptide Peptidase 4 (DPP-4) Inhibitors Products Offered
- 11.4.5 Boehringer Ingelheim Recent Development
- 11.5 Takeda Pharmaceutical Company
- 11.5.1 Takeda Pharmaceutical Company Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Takeda Pharmaceutical Company Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Takeda Pharmaceutical Company Dipeptide Peptidase 4 (DPP-4) Inhibitors Products Offered
- 11.5.5 Takeda Pharmaceutical Company Recent Development
- 11.6 BMS
- 11.6.1 BMS Company Details
- 11.6.2 Company Business Overview
- 11.6.3 BMS Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 BMS Dipeptide Peptidase 4 (DPP-4) Inhibitors Products Offered
- 11.6.5 BMS Recent Development
12 Future Forecast
- 12.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Forecast by Regions
- 12.1.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Forecast by Regions 2019-2025
- 12.1.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Forecast by Regions 2019-2025
- 12.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Forecast by Product
- 12.2.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Forecast by Product 2019-2025
- 12.2.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Forecast by Product 2019-2025
- 12.3 Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Forecast by End User
- 12.4 North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Forecast
- 12.5 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Forecast
- 12.6 Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Forecast
- 12.7 Central & South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Forecast
- 12.8 Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Dipeptide Peptidase 4 (DPP-4) Inhibitors . Industry analysis & Market Report on Dipeptide Peptidase 4 (DPP-4) Inhibitors is a syndicated market report, published as Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Dipeptide Peptidase 4 (DPP-4) Inhibitors market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
